Protocol Ledger

NCT06717958 · Phase II · RECRUITING

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutati

Interventional Phase II clinical trial protocol NCT06717958 sponsored by Technische Universität Dresden in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-17 Enrollment: 76 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06717958
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)76 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06717958
Protocol FieldVerified Registry Value
NCT IdentifierNCT06717958
Consolidated Lead SponsorTechnische Universität Dresden
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment76 participants (ESTIMATED)
Registered Start Date2025-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06717958
Hospital Research SiteLocationSite Profile
Klinikum Chemnitz gGmbHChemnitz, GermanyOpen Hospital Dossier ->
Universitätsklinikum EssenEssen, GermanyOpen Hospital Dossier ->
Universitätsklinikum JenaJena, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI